1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow XP 23829 800 mg QD: new trials by email Literature Review of XP 23829 800 mg QD trials Research Report on XP 23829 800 mg QD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis XP23829 400 mg QD, XP 23829 800 mg QD, XP23829 400 mg BID - Psoriasis | Phase 2 | Completed | Dr. Reddy's Laboratories Limited | 200 | 2014-06-01 | 2022-04-12 |
Psoriasis (1)
Dr. Reddy's Laboratories Limited (1)
United States (1)